Janus Kinase Inhibitors: all 1,428 studies that test it
Page 14 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and MetforminCompletedNCT02760342Phase 1
- Trial Ruxolitinib and Peg-interferon Alpha-2a Combination in Patients With Primary Myelofibrosis RUXOPegCompletedNCT02742324Phase 1/2
- A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic LeukemiaCompletedNCT02723994Phase 2
- Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse PsoriasisCompletedNCT02695940Phase 2
- Bioavailability Study Of PF-06651600 In Healthy SubjectsCompletedNCT02684760Phase 1
- Multicenter Study of Pacritinib Combined With Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)WithdrawnNCT02677948Phase 1/2
- Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) PatientsStatus unknownNCT02665910Phase 1
- Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand EczemaCompletedNCT02664805Phase 2
- SAD and MAD Study to Evaluate Safety, Tolerability, and Pharmacokinetics (PK) of TD-1473 in Healthy SubjectsCompletedNCT02657122Phase 1
- Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid TumorsCompletedNCT02646748Phase 1
- Genomics-Based Target Therapy for Children With Relapsed or Refractory MalignancyStatus unknownNCT02638428Phase 2
- Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHDCompletedNCT02614612Phase 1
- Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory LymphomaCompletedNCT02613598Phase 1
- Pharmacokinetics Study in Patients With Impaired Renal Function and Subjects With Normal Renal FunctionCompletedNCT02603497Phase 1
- Pharmacodynamic Effects and Predictive Biomarkers With Ruxolitinib in Operable Head and Neck CancerWithdrawnNCT02593929Early Phase 1
- Pharmacokinetics Study in Patients With Impaired Hepatic FunctionCompletedNCT02586194Phase 1
- A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacritinib in MyelofibrosisWithdrawnNCT02584777Phase 2
- The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential ThrombocythemiaActive, not recruitingNCT02577926Phase 2
- An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural PerspectiveCompletedNCT02566967Phase 3
- Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS)WithdrawnNCT02564536Phase 1
- Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus ErythematosusCompletedNCT02535689Phase 1
- Bioequivalence Evaluation of a New and Current Tablet of ASP015KCompletedNCT02531191Phase 1
- Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With MyelofibrosisWithdrawnNCT02528877Phase 1
- Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or OlderActive, not recruitingNCT02494882Phase 1
- TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to HydroxyureaCompletedNCT02493530Phase 1
- Ruxolitinib in Combination With AutotransplantWithdrawnNCT02469974Not applicable
- INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin LymphomaTerminatedNCT02456675Phase 2
- First-in-Human Single Ascending Dose of SHR0302Status unknownNCT02423538Phase 1
- CINC424A2X01B Rollover ProtocolActive, not recruitingNCT02386800Phase 4
- Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWithdrawnNCT02355431Phase 2
- Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02342353Phase 1
- Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
- Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedNCT02257619Phase 2
- Safety and Tolerability of Combined Treatment With Nilotinib and Ruxolitinib in CML and Ph+ ALL PatientsCompletedNCT02253277Phase 1
- Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02206763Phase 1
- JAK-inhibition in Recurrent Classical Hodgkin LymphomaCompletedNCT02164500Phase 2
- AStudy to Evaluate the Bioavailability of PF 04965842 in Healthy SubjectsCompletedNCT02163161Phase 1
- Multiple Ascending Dose Study of GLPG0634 in Japanese and Caucasian Healthy SubjectsCompletedNCT02162355Phase 1
- INCB047986 in Rheumatoid ArthritisTerminatedNCT02151474Phase 2
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy SubjectsCompletedNCT02141425Phase 1
- Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02131584Phase 2
- A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult SubjectsCompletedNCT02111317Phase 1
- Randomized Open-Label Study of INCB047986 in Subjects With Primary Myelodysplastic Syndrome (MDS)TerminatedNCT02093429Phase 1/2
- Study to Evaluate GLPG0634 in Subjects With Renal Impairment Compared to Healthy SubjectsCompletedNCT02084199Phase 1
- Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AMLCompletedNCT02076191Phase 1/2
- Study of Ruxolitinib in the Treatment of Cachexia in Patients With Tumor-Associated Chronic Wasting Diseases.TerminatedNCT02072057Phase 2
- Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's DiseaseCompletedNCT02048618Phase 2
- Ruxolitinib in the Treatment of Chronic Lymphocytic LeukemiaCompletedNCT02015208Phase 1/2
- Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential ThrombocythemiaTerminatedNCT01998828Phase 2
- Pilot Study of Ruxolitinib in Relapsed or Refractory Hodgkin Lymphoma and Primary Mediastinal Large B-cell LymphomaCompletedNCT01965119Phase 2
- Drug-Drug Interaction Study Evaluating Effects of ASP015K on RosuvastatinCompletedNCT01959399Phase 1
- A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedNCT01959282Phase 2
- A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult SubjectsCompletedNCT01929577Phase 1
- Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-LeukemiaCompletedNCT01914484Phase 1/2
- Study of INCB040093 in Subjects With Previously Treated B-Cell MalignanciesCompletedNCT01905813Phase 1
- Ruxolitinib for Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)CompletedNCT01895842Phase 1
- A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's LymphomaCompletedNCT01877005Phase 2
- Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid TumorsCompletedNCT01858883Phase 1/2
- Effect of SAR302503 on ECG Activity in Patients With Solid TumorsCompletedNCT01836705Phase 1
- First-in-Human Study to Evaluate Safety and Tolerability of Single and Multiple Ascending Doses of Janus Kinase-1 Inhibitor PF-04965842 in Healthy Western and Japanese SubjectsCompletedNCT01835197Phase 1
- A Phase I, Open Interaction Study Between GLPG0634 and Midazolam in Healthy SubjectsCompletedNCT01798979Phase 1
- JAK2 Inhibitors RUXOLITINIB in Patients With MyelofibrosisCompletedNCT01795677Phase 2
- Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative NeoplasmCompletedNCT01787487Phase 2
- Open Label Pharmacokinetic Study of SAR302503 in Subjects With Renal ImpairmentCompletedNCT01763190Phase 1
- Open Label Pharmacokinetic Study of SAR302503 in Subjects With Hepatic ImpairmentCompletedNCT01762462Phase 1
- A Drug Interaction Study to Evaluate the Pharmacokinetics of ASP015K and Methotrexate in Patients With Rheumatoid ArthritisCompletedNCT01754805Phase 1
- Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase InhibitorsTerminatedNCT01751425Phase 1
- A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494CompletedNCT01741493Phase 1
- A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary MyelofibrosisTerminatedNCT01730248Phase 1
- A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis StudyCompletedNCT01711814Phase 2
- Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) PatientsCompletedNCT01702064Phase 1
- Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With SplenomegalyCompletedNCT01692366Phase 2
- A Phase I Study to Compare 3 Different Strengths of an Extended Release Formulation of ASP015K to an Immediate Release Formulation of ASP015KCompletedNCT01686217Phase 1
- Dose-ranging Study With GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01668641Phase 2
- Single and Multiple Dose Pharmacokinetics of GLPG0634 in Elderly Healthy SubjectsCompletedNCT01665924Phase 1
- A Study to Evaluate the Efficacy and Safety of ASP015K in Moderate to Severe Rheumatoid Arthritis SubjectsCompletedNCT01649999Phase 2
- Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MFCompletedNCT01644110Phase 1/2
- A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque PsoriasisCompletedNCT01634087Phase 2
- An Open Label Study of Itacitinib Administered Orally in Patients With MyelofibrosisCompletedNCT01633372Phase 2
- A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid ArthritisCompletedNCT01626573Phase 2
- Tofacitinib Bioequivalence Study Comparing Tablets And CapsulesCompletedNCT01599377Phase 1
- A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsActive, not recruitingNCT01594723Phase 2
- Drug Interaction Study of SAR302503 in Patients With Solid TumorCompletedNCT01585623Phase 1
- A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid ArthritisCompletedNCT01565655Phase 2
- A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateCompletedNCT01554696Phase 2
- Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative NeoplasmsCompletedNCT01520220Phase 1
- A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy VolunteersCompletedNCT01499004Phase 1
- A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015KCompletedNCT01486017Phase 1
- A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New FormulationCompletedNCT01484964Phase 1
- Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisCompletedNCT01433445Phase 1
- A Study to Assess the Bioavailability of ASP015KCompletedNCT01430078Phase 1
- Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Tacrolimus in Healthy VolunteersCompletedNCT01430065Phase 1
- Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia MyelofibrosisCompletedNCT01423058Phase 1/2
- Study With SAR302503 in Patients With Polycythemia Vera or Essential ThrombocythemiaCompletedNCT01420783Phase 2
- Phase 2 Study of SAR302503 in Patients With MyelofibrosisCompletedNCT01420770Phase 2
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of GLPG0634 in Healthy SubjectsCompletedNCT01419990Phase 1
- A Study to Assess the Pharmacokinetics of ASP015K in Healthy Male SubjectsCompletedNCT01406132Phase 1
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015KCompletedNCT01387087Phase 1
- Safety and Preliminary Efficacy of GLPG0634 in Methotrexate-refractory Active Rheumatoid Arthritis PatientsCompletedNCT01384422Phase 2
- Pharmacokinetic Interaction Study to Assess the Effect of ASP015K on Mycophenolate Mofetil in Healthy VolunteersCompletedNCT01364987Phase 1